Pre-clinical evaluation of rHDL encapsulated retinoids for the treatment of neuroblastoma

Frontiers in Pediatrics

Volumn 1, Issue MAR, 2013, Pages

  Sabnis, Nirupama ^a   Pratap, Suraj ^b   Akopova, Irina ^a   Bowman, Paul W ^c   Lacko, Andras G ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b Downstate Health Sciences University   (United States)

^c University of North Texas Health Science Center   (United States)

Author keywords

All trans retinoic acid; Drug delivery; Fenretinide; Nanoparticles; Neuroblastoma; rHDL

Indexed keywords

EID: 84904645974     PISSN: None     EISSN: 22962360     Source Type: Journal    
DOI: 10.3389/fped.2013.00006     Document Type: Article

References (70)

1. Mueller S, and Matthay K. Neuroblastoma biology and staging. Curr Oncol Rep (2009) 11:431-8.
2. Zage P, Louis C, and Cohn S. New aspects of neuroblastoma treatment: ASPHO 2011 symposium review. Pediatr Blood Cancer (2011) 58(7):1099-105.
3. Maris J, Hogarty M, Bagruell R, and Cohn S. Neuroblastoma. Lancet (2007) 369:2106-20.
4. Bowen K, and Chung D. Recent advances in neuroblastoma. Curr Opin Pediatr (2009) 21(3):350-6.
5. Verissimo C, Molenaar J, Fitzsimons C, and Vreugdenhil E. Neuroblastoma therapy: what is in the pipeline? Endocr Relat Cancer (2011) 18(6):213-31.
6. London W, Cascel V, Monclair T, Ambros P, Pearson A, Cohn S, et al. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol (2011) 29:3286-92.
7. Gains J, Mandeville H, Cork N, Brock P, and Gaze M. Ten challenges in the management of neuroblastoma. Future Oncol (2012) 8(7):839-58.
8. Matthay K, George R, and Yu A. Promising therapeutic targets in neuroblastoma. Clin Cancer Res (2012) 18(10):2740-53.
9. Modak S, and Cheung N. Neuroblastoma: therapeutic strategies for a clinical enigma. Cancer Treat Rev (2010) 36(4):307-17.
10. Donfrancesco A, Jenkner A, Castellano A, Ilari I, Milano G, De Sio L, et al. Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age. Acta Pediatr Suppl (2004) 93(445):6-11.
11. Izycka-Swieszewska E, Drozynska E, Rzepko R, Kobierska-Gulida G, Grajkowska W, Perek D, et al. Analysis of PI3K/AKT/mTOR signaling pathway in high risk neuroblastic tumours. Pol J Pathol (2010) 61(4):192-8.
12. Izycka-Swieszewska E, Brzeskwiniewicz M, Wozniak A, Drozynska E, Grajkowska W, Perek D, et al. EGFR, PIK3CA and PTEN gene status and their protein product expression in neuroblastic tumours. Folia Neuropathol (2010) 48(4):238-45.
13. Li Z, Yan S, Attayan N, Ramalingam S, and Thiele C. Combination of an allosteric Akt inhibitor MK-2206 with etoposide or rapamycin enhances the antitumor growth effect in neuroblastoma. Clin Cancer Res (2012) 18(13):3603-15.
14. Navid F, Armstrong M, and Barfield R. Immune therapies for neuroblastoma. Cancer Biol Ther (2009) 8(10):874-82.
15. Modak S, and Cheung N. Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest (2007) 25(1):67-77.
16. Yu A, Gilman A, Ozkaynak M, London W, Kreissman S, Chen H, et al. Children's Oncology Group. Anti-GD2 antibody with GMCSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med (2010) 363(14):1324-34.
17. Cole K, and Maris J. New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome. Clin Cancer Res (2012) 18(9):2423-8.
18. Barna G, Sebestyén A, Weischede S, Peták I, Mihalik R, Formelli F, et al. Different ways to induce apoptosis by fenretinide and all-trans-retinoic acid in human B lymphoma cells. Anticancer Res (2005) 25(6B):4179-85.
19. Tamura K, Nakae D, Horiguchi K, Akai H, Kobayashi Y, Andoh N, et al. Inhibition by N-(4-hydroxyphenyl) retinamide and all-trans-retinoic acid of exogenous and endogenous development of putative preneoplastic, glutathione S-transferase placental form-positive lesions in the livers of rats. Carcinogenesis (1997) 18(11):2133-41.
20. Decensi A, Torrisi R, Polizzi A, Gesi R, Brezzo V, Rolando M, et al. Effect of the synthetic retinoid fenretinide on dark adaptation and the ocular surface. J Natl Cancer Inst (1994) 86:105-10.
21. Redova M, Chlapek P, Loja T, Zitterbart K, Hermanova M, Sterba J, et al. Influence of LOX/COX inhibitors on cell differentiation induced by all-trans retinoic acid in neuroblastoma cells. Int J Mol Med (2010) 25:271-80.
22. Connolly R, Nguyen N, and Sukumar S. Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment. Clin Cancer Res (2013). doi:10.1158/1078-0432.CCR-12-3175
23. Xie H, Zhu F, Huang Z, Lee M, Kim D, Li X, et al. Identification of mammalian target of rapamycin as a direct target of fenretinide both in vitro and in vivo. Carcinogenesis (2012) 33(9):1814-21.
24. Cazzaniga M, Varricchio C, Montefrancesco C, Feroce I, and Guerrieri-Gonzaga A. Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk? J Biomed Biotechnol (2012) 2012:172897-906.
25. Um S, Sin H, Han H, Kwon Y, Kim E, Park S, et al. Potent cytotoxic effects of novel retinamide derivatives in ovarian cancer cells. Biol Pharm Bull (2003) 26(10):1412-19.
26. Ozpolat B, Tari A, Mehta K, and Lopez-Berestein G. Nuclear retinoid receptors are involved in N-(4-hydroxyphenyl) retinamide (Fenretinide)-induced gene expression and growth inhibition in HL-60 acute myeloid leukemia cells. Leuk Lymphoma (2004) 45(5):979-85.
27. Reynolds CP, Matthay KK, Villablanca JG, and Maurer BJ. Retinoid therapy of high-risk neuroblastoma. Cancer Lett (2003) 197(1-2):185-92.
28. Ranganathan R, Madanmohan S, Kesavan A, Baskar G, Krishnamoorthy Y, Santosham R, et al. Nanomedicine: towards development of patient-friendly drug-delivery systems for oncological applications. Int J Nanomedicine (2012) 7:1043-60.
29. Bollag W, and Holdener E. Retinoids in cancer prevention and therapy. Ann Oncol (1992) 3:513-26.
30. Figueiredo M, and Esenaliev R. PLGA nanoparticles for ultrasound-mediated gene delivery to solid tumors. J Drug Deliv (2012) 2012:767839-59.
31. Siddiqui I, Adhami V, Chamcheu J, and Mukhtar H. Impact of nanotechnology in cancer: emphasis on nanochemoprevention. Int J Nanomedicine (2012) 7:591-605.
32. Sabnis N, and Lacko A. Drug delivery via lipoprotein-based carriers: answering the challenges in systemic therapeutics. Ther Deliv (2012) 3(5):599-608.
33. Zheng G, Chen J, Li H, and Glickson J. Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proc Natl Acad Sci USA (2005) 102(49):17757-62.
34. Yang M, Chen J, Cao W, Ding L, Ng K, Jin H, et al. Attenuation of nontargeted cell-kill using a high-density lipoprotein-mimicking peptide-phospholipid nanoscaffold. Nanomedicine (Lond.) (2011) 6(4):631-41.
35. Wu J, Liu Q, and Lee R. A folate receptor-targeted liposomal formulation for paclitaxel. Int J Pharm (2006) 316(1-2):148-153.
36. Sabnis N, Nair M, Israel M, McConathy W, and Lacko A. Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles. Int J Nanomedicine (2012) 7:975-83.
37. McConathy W, Paranjape S, Mooberry L, Buttreddy S, Nair M, and Lacko A. Validation of the reconstituted high-density lipoprotein (rHDL) drug delivery platform using dilauryl fluorescein (DLF). Drug Deliv Transl Res (2011) 1(2):113-20.
38. Lacko A, Nair M, Prokai L, and McConathy W. Prospects and challenges of the development of lipoprotein-based formulations for anti-cancer drugs. Expert Opin Drug Deliv (2007) 4(6):665-75.
39. Ng K, Lovell J, and Zheng G. Lipoprotein inspired nanoparticles for cancer theranostics. Acc Chem Res (2011) 44(10):1105-13.
40. McConathy W, Nair M, Paranjape S, Mooberry L, and Lacko A. Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. Anticancer Drugs (2008) 19(2):183-8.
41. Mooberry L, Nair M, Paranjape S, McConathy W, and Lacko A. Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. J Drug Target (2010) 18(1):53-8.
42. Counsell R, and Pohland R. Lipoproteins as potential site-specific delivery systems for diagnostic and therapeutic agents. J Med Chem (1982) 25(10):1115-20.
43. Gomaa M, Armstrong J, Bobillon B, Veal G, Brancale A, Redfern C, et al. Novel azolyl-(phenylmethyl)]-aryl/heteroarylamines: potent CYP26 inhibitors and enhancers of all-trans retinoic acid activity in neuroblastoma cells. Bioorg Med Chem (2008) 16(17):8301-13.
44. Jeddi R, Ghédira H, Ben Abdennebi Y, Kacem K, Ben Amor R, Aissaoui L, et al. ATRA and anthracycline-based chemotherapy in the treatment of childhood acute promyelocytic leukemia (APL): A 10-year experience in Tunisia. Med Oncol (2011) 28(4):1618-23.
45. Reynolds C, and Lemons R. Retinoid therapy of childhood cancer. Hematol Oncol Clin North Am (2001) 15(5):867-910.
46. Villablanca J, London W, Naranjo A, McGrady P, Ames M, Reid J, et al. Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group. Clin Cancer Res (2011) 17(21):6858-66.
47. Formelli F, Cavadini E, Luksch R, Garaventa A, Appierto V, and Persiani S. Relationship among pharmacokinetics and pharmacodynamics of fenretinide and plasma retinol reduction in neuroblastoma patients. Cancer Chemother Pharmacol (2010) 66(5):993-8.
48. Ryan R, Forte T, and Oda M. Optimized bacterial expression of human apolipoprotein A-I. Protein Expr Purif (2003) 27(1):98-103.
49. Raffin R, Colomé L, Schapoval E, Jornada D, Pohlmann A, and Guterres S. Gastro-resistant microparticles containing sodium pantoprazole: stability studies and in vivo anti-ulcer activity. Open Drug Deliv J (2007) 1:28-35.
50. Gilbert L, and Wachsman J. Characterization and partial purification of the plasminogen activator from human neuroblastoma cell line, SK-N-SH. A comparison with human urokinase. Biochim Biophys Acta (1982) 704:450-60.
51. Dunn K, Aotaki-Keen A, Putkey F, and Hjelmeland L. ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exp Eye Res (1996) 62:155-69.
52. Loney W, Kudchodkar B, Weiss S, Clearfield M, Shores J, and Lacko A. Evaluation of gemfibrozil therapy: predictive response from lipoprotein sub fraction analysis. Am J Ther (1997) 4(9-10):301-9.
53. Nieland T, Penman M, Dori L, Krieger M, and Kirchhausen T. Discovery of chemical inhibitors of the selective transfer of lipids mediated by the HDL receptor SR-BI. Proc Natl Acad Sci USA (2002) 99(24):15422-27.
54. Holmquist L, and Carlson L. Subfractionation and characterization of native and incubation enlarged human plasma high density lipoprotein particles by high performance gel filtration. Lipids (1985) 20(6):378-88.
55. Baalousha M, and Lead J. Rationalizing nanomaterial sizes measured by atomic force microscopy, flow field-flow fractionation, and dynamic light scattering: sample preparation, polydispersity, and particle structure. Environ Sci Technol (2012) 46(11):6134-42.
56. Melichar B, and Zezulová M. The significance of altered gastrointestinal permeability in cancer patients. Curr Opin Support Palliat Care (2011) 5(1):47-54.
57. Arias JL. Drug targeting strategies in cancer treatment: an overview. Mini Rev Med Chem (2011) 11(1):1-17.
58. Thompson J, Zamboni W, Cheshire P, Richmond L, Luo X, Houghton J, et al. Efficacy of oral irinotecan against neuroblastoma xenografts. Anticancer Drugs (1997) 8(4):313-22.
59. Richard J. Challenges and opportunities in the delivery of cancer therapeutics. Ther Deliv (2011) 2(1):107-21.
60. Wu J, DiPietrantonio A, and Hsieh T. Mechanism of fenretinide (4-HPR)-induced cell death. Apoptosis (2001) 6(5):377-88.
61. Di Vinci A, Geido E, Infusini E, and Giaretti W. Neuroblastoma cell apoptosis induced by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. Int J Cancer (1994) 59:422-26.
62. Springer L, and Stewart B. N-(4-hydroxyphenyl) retinamide induced death in human lymphoblastoid cells: 50 kb DNA breakage as a means of distinguishing apoptosis from necrosis. Cancer Lett (1998) 128:189-96.
63. Igawa M, Tanabe T, Chodak G, and Rukstalis D. N-(4-hydroxyphenyl) retinamide induces cell cycle specific growth inhibition in PC-3 cells. Prostate (1994) 24:299-305.
64. Herrmann K. Teratogenic effects of retinoic acid and related substances on the early development of the zebrafish Brachydanio rerio as assessed by a novel scoring system. Toxicol In vitro (1995) 9(3):267-83.
65. Petrie K, Zelent A, and Waxman S. Differentiation therapy of acute myeloid leukemia: past, present and future. Curr Opin Hematol (2009) 16(2):84-91.
66. Holmes D, Vishnu P, Dorer RK, and Aboulafia DM. All-trans retinoic acid-induced pseudotumor cerebri during induction therapy for acute promyelocytic leukemia: a case report and literature review. Case Rep Oncol Med (2012) 2012:313057-68.
67. Armstrong J, Martin S, Illingworth N, Jamieson D, Neilson A, Lovat P, et al. The impact of retinoic acid treatment on the sensitivity of neuroblastoma cells to fenretinide. Oncol Rep (2012) 27(1):293-8.
68. Shahzad M, Lingegowda M, Han H, Lu C, Bottsford-Miller J, Mora E, et al. Targeted Delivery of Small Interfering RNA Using rHDL Nanoparticles. Neoplacia (2011) 13(4):309-19.
69. Leon C, Locke J, Adomat H, Etinger S, Twiddy A, Neumann R, et al. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate (2010) 70(4):390-400.
70. Lou B, Liao X, Wu M, Cheng P, Yin C, and Fei Z. High-density lipoprotein as a potential carrier for delivery of a lipophilic antitumoral drug into hepatoma cells. World J Gastroenterol (2005) 11(7):954-9.